P22-2 A Single Center Treatment Experience of Combination with Chemotherapy and Nivolumab for HER2-negative Gastric Cancer

Kai Tsugaru,Takeshi Kawakami,Daiki Kawaguchi,Ari Nishimura,Kunihiro Fushiki,Kotoe Oshima,Takahiro Tsushima,Akiko Todaka,Satoshi Hamauchi,Tomoya Yokota,Yusuke Onozawa,Hirofumi Yasui,Kentaro Yamazaki

Annals of oncology（2023）

引用 0|浏览33

暂无评分

摘要

Two international phase 3 studies reported that chemotherapy plus nivolumab (CT+NIVO) in the first-line treatment improved clinical outcomes in patients with HER2-negative advanced gastric cancer (AGC). However, its efficacy and safety in clinical practice have not been well reported.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要